Compare AFYA & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AFYA | NVCR |
|---|---|---|
| Founded | 1999 | 2000 |
| Country | Brazil | Switzerland |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2019 | 2015 |
| Metric | AFYA | NVCR |
|---|---|---|
| Price | $15.94 | $12.68 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $17.00 | ★ $28.08 |
| AVG Volume (30 Days) | 109.9K | ★ 1.1M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | ★ 4.36% | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $655,353,000.00 |
| Revenue This Year | $10.43 | $7.72 |
| Revenue Next Year | $7.15 | $6.74 |
| P/E Ratio | $9.30 | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $13.00 | $9.82 |
| 52 Week High | $19.76 | $20.05 |
| Indicator | AFYA | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 66.99 | 60.84 |
| Support Level | $14.02 | $12.66 |
| Resistance Level | $15.88 | $13.34 |
| Average True Range (ATR) | 0.46 | 0.54 |
| MACD | 0.06 | 0.29 |
| Stochastic Oscillator | 83.51 | 84.84 |
Afya Ltd is a medical education group based in Brazil. Its education portfolio has several courses in addition to Medicine, such as Management, Dentistry, Law, Engineering, Nursing, Psychology, and Accounting Sciences, among others. It has three segments; Undergrad provides educational services through undergraduate courses related to medical school, undergraduate health science and other ex-health undergraduate programs, Continuing Education provides medical education, specialization and graduate courses in medicine, delivered through digital and in-person content; and Medical practice solution provides clinical decision, clinical management and doctor-patient relationships for physicians and provide access, demand and efficiency for the healthcare players.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.